Lenmeldy (atidarsagene autotemcel) - MEDICAID - VIRGINIA

This policy covers atidarsagene autotemcel (Lenmeldy), a one‑time lentiviral hematopoietic stem‑cell gene therapy for metachromatic leukodystrophy (MLD), primarily for early‑onset disease and specifically the PSLI, PSEJ, or ESEJ subtypes. Coverage is limited to patients who are candidates for allogeneic HSCT but lack an available matched donor (or have no residual donor cells after a prior transplant), is restricted to a single lifetime dose, requires Corporate Transplant Department referral and medical director review, and excludes those with significant active infections, hepatic impairment, or other specified contraindications.

"Leukodystrophies are a group of genetically determined disorders that affect development or maintenance of central nervous system myelin (white matter)."

Sign up to see full coverage criteria, indications, and limitations.